{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277523","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.073713+00:00","generated_at":"2026-05-16T21:16:45.490134+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data","bullets":["Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.","Phase 3 NEAT enrollment completed (105 participants); topline results expected first quarter 2026.","iDSMB recommended study continue without modifications; 100% of patients chose open-label extension.","Net loss $13.3M ($0.25/sh); R&D expenses $8.1M, G&A expenses $3.3M for Q3 2025.","FDA Fast Track designation; NDA submission planned H2 2026 assuming positive study results."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277523","json":"https://secwatch.observer/filing/0001193125-25-277523.json","markdown":"https://secwatch.observer/filing/0001193125-25-277523.md","text":"https://secwatch.observer/filing/0001193125-25-277523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/0001193125-25-277523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/qncx-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:16:45.490134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}